CBPO [China Biologic Products] 424B5: PROSPECTUS SUPPLEMENT Page
[PROSPECTUS SUPPLEMENT Page]
CBPO [China Biologic Products] S-3ASR: (Original Filing)
[CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered (1) Amount To] [June 5, 2015 China Biologic Products, Inc. Re: Registration Statement on Form S-3 Ladies and Gentlemen: Registration Statement Company Commission Act At your request, we have examined the Registration Statement on Form S-3ASR (the “ Common Stock Preferred Stock Units Company Securities Selling Stockholder Selling Stockholder Securities Securities Prospectus Prospectus Supplement The Securities are to be sold from time to] [China Biologic Products, INC. COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES Year ended December 31, Three months 2010 2011 2012 2013 2014 2015 Fixed charges: Interest expensed and capitalized $ 1,087,290 $ 1,147,315 $ 1,249,982 $ 1,114,851 $ 3,677,703 $ 751,810 Amortized premiums, discounts and capitalized expenses related to indebtedness 1,578,014 3,503,766 - - - - Estimation of the] [Consent of Independent Registered Public Accounting Firm The Board of Directors We consent to the use of our reports with respect to the consolidated financial statements and the effectiveness of internal control over financial reporting incorporated by reference herein and to the reference to our firm under the heading “Experts” in the prospectus. Hong Kong, China June 5, 2015]
CBPO [China Biologic Products] S-3ASR: CALCULATION OF REGISTRATION FEE Title of Each Class
[CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered (1) Amount To] [June 5, 2015 China Biologic Products, Inc. Re: Registration Statement on Form S-3 Ladies and Gentlemen: Registration Statement Company Commission Act At your request, we have examined the Registration Statement on Form S-3ASR (the “ Common Stock Preferred Stock Units Company Securities Selling Stockholder Selling Stockholder Securities Securities Prospectus Prospectus Supplement The Securities are to be sold from time to] [China Biologic Products, INC. COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES Year ended December 31, Three months 2010 2011 2012 2013 2014 2015 Fixed charges: Interest expensed and capitalized $ 1,087,290 $ 1,147,315 $ 1,249,982 $ 1,114,851 $ 3,677,703 $ 751,810 Amortized premiums, discounts and capitalized expenses related to indebtedness 1,578,014 3,503,766 - - - - Estimation of the] [Consent of Independent Registered Public Accounting Firm The Board of Directors We consent to the use of our reports with respect to the consolidated financial statements and the effectiveness of internal control over financial reporting incorporated by reference herein and to the reference to our firm under the heading “Experts” in the prospectus. Hong Kong, China June 5, 2015]
CBPO [China Biologic Products] 8-K: (Original Filing)
[FOR RELEASE May 6, 2015 China Biologic Reports Financial Results for the First Quarter of 2015 1Q15 Total Sales Increases 25% to $70.4 Million 1Q15 Non-GAAP Net Income Increases 30.9% to $ 25.0 Million Raises FY15 Total Sales Forecast BEIJING, China – May 6, 2015 – First Quarter 2015 Financial Highlights · Total sales · Gross profit · Income from] []
CBPO [China Biologic Products] 8-K: FOR RELEASE May 6, 2015 China Biologic Reports
[FOR RELEASE May 6, 2015 China Biologic Reports Financial Results for the First Quarter of 2015 1Q15 Total Sales Increases 25% to $70.4 Million 1Q15 Non-GAAP Net Income Increases 30.9% to $ 25.0 Million Raises FY15 Total Sales Forecast BEIJING, China – May 6, 2015 – First Quarter 2015 Financial Highlights · Total sales · Gross profit · Income from] []
CBPO [China Biologic Products] IRANNOTICE: (Original Filing)
[China Biologic Products, Inc. 8th Floor, Jialong International Building 19 Chaoyang Park Road Chaoyang District, Beijing 100125 People’s Republic of China May 6, 2015 VIA EDGAR 100 F Street, N.E. Re: Notice of Disclosure Filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the]
CBPO [China Biologic Products] IRANNOTICE: China Biologic Products, Inc. 8th Floor, Jialong International
[China Biologic Products, Inc. 8th Floor, Jialong International Building 19 Chaoyang Park Road Chaoyang District, Beijing 100125 People’s Republic of China May 6, 2015 VIA EDGAR 100 F Street, N.E. Re: Notice of Disclosure Filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the]
CBPO [China Biologic Products] 10-Q: (Original Filing)
[] [CERTIFICATIONS I, David (Xiaoying) Gao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Ming Yang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th David (Xiaoying) Gao Chief Executive Officer] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th Ming Yang Chief Financial Officer (Principal Financial Officer)]
CBPO [China Biologic Products] 10-Q:
[] [CERTIFICATIONS I, David (Xiaoying) Gao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Ming Yang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th David (Xiaoying) Gao Chief Executive Officer] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th Ming Yang Chief Financial Officer (Principal Financial Officer)]
CBPO [China Biologic Products] DEFA14A: (Original Filing)
[SCHEDULE 14A x ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ ¨ Definitive Proxy Statement x Definitive Additional Materials ¨ Soliciting Material under Rule 14a-12 CHINA BIOLOGIC PRODUCTS, INC. ________________________________________________________ Payment of Filing Fee (Check the appropriate box): x No fee required ¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of]
